Anti-human interleukin 23 monoclonal antibody and application thereof
The present invention relates to an anti-human interleukin 23 (hIL-23) monoclonal antibody and an application thereof. The anti-human interleukin 23 (hIL-23) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein (a): the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, (b): the amino acid sequence of the CDR-H2 is as shown in SEQ ID NO: 2, (c): the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3, (d): the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4, (e): the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5, and (f): the amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. Compared with existing anti-human interleukin 23 monoclonal antibodies (Guselkumab and Risankizumab), the hIL-23 binding affinity of the anti-human interleukin 23 (hIL-23) monoclonal antibody is equivalent, but the antagonistic activity at the cellular level is superior to Guselkumab, and equivalent to Risankizumab.
1 . An isolated anti-human interleukin 23 monoclonal antibody, comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
(a) the amino acid sequence of CDR-H1 consists of SEQ ID NO: 1;
(b) the amino acid sequence of CDR-H2 consists of SEQ ID NO: 2;
(c) the amino acid sequence of CDR-H3 consists of SEQ ID NO: 3;
(d) the amino acid sequence of CDR-L1 consists of SEQ ID NO: 4;
(e) the amino acid sequence of CDR-L2 consists of SEQ ID NO: 5; and
(f) the amino acid sequence of CDR-L3 consists of SEQ ID NO: 6.
2 . The monoclonal antibody according to claim 1 , which comprises a heavy chain variable region and a light chain variable region, wherein
the amino acid sequence of the heavy chain variable region consists of SEQ ID NO: 7; and,
the amino acid sequence of the light chain variable region consists of SEQ ID NO: 8.
3 . A pharmaceutical composition, comprising the monoclonal antibody according to claim 1 , and a pharmaceutically acceptable carrier.
4 . The pharmaceutical composition according to claim 3 , which is used for treatment of a disease related to IL-23 mediated signal transduction;
wherein the disease related to IL-23 mediated signal transduction is selected from the group consisting of: psoriatic arthritis, inflammatory bowel disease, and psoriasis.
5 . The pharmaceutical composition according to claim 4 , wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.